Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
Purpose: This article reviews the essential clinical trials that have led to these immunotherapy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to identify patients who are most likely to benefit from immunotherapies. Methods: This case review serie...
Main Authors: | Frederic Karim, Adina Amin, Marie Liu, Nivetha Vishnuvardhan, Saif Amin, Raffey Shabbir, Brandon Swed, Uqba Khan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/16/4099 |
Similar Items
-
An Ailment with Which I Will Contend: A Narrative Review of 5000 Years of Esophagogastric Cancers and Their Treatments, with Special Emphasis on Recent Advances in Immunotherapeutics
by: C. Beau Hilton, et al.
Published: (2024-01-01) -
Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies
by: Emer Lynch, et al.
Published: (2023-11-01) -
Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
by: Meng Chen, et al.
Published: (2022-11-01) -
Therapeutic Advances in the Treatment of Gastroesophageal Cancers
by: Jenny J. Li, et al.
Published: (2023-05-01) -
Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
by: Emer Lynch, et al.
Published: (2023-01-01)